<p>Researchers from the Icahn School of Medicine at Mount Sinai, in collaboration with the <a href="https://proteomics.cancer.gov/programs/cptac">Clinical Proteomic Tumor Analysis Consortium</a> of the National Institutes of Health, The University of Texas MD Anderson Cancer Center, Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine, and others, have unveiled a detailed understanding of immune responses in cancer, marking a significant development in the field. The findings were published in the February 14 online issue of <em>Cell</em>. Utilizing data from more than 1,000 tumors across 10 different cancers, the study is the first to integrate DNA, RNA, and <a href="https://www.sciencedirect.com/topics/neuroscience/proteomics">proteomics</a><u> (the study of proteins)</u>, revealing the complex interplay of immune cells in tumors. The data came from the Clinical Proteomic Tumor Analysis Consortium (CPTAC), a program under the National Cancer Institute.</p>